EMAIL: SFeldman@olshanlaw.com

DIRECT DIAL: 212.451.2234

VIA EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Ladies and Gentlemen:

On behalf of Alzamend Neuro, Inc., a Delaware corporation, we hereby submit in electronic format for filing with the U.S. Securities and Exchange Commission (the “Commission”), pursuant to the Securities Act of 1933, as amended (the “Securities Act”), and Rule 101(a)(1)(i) of Regulation S-T, one copy of the final prospectus relating to Alzamend Neuro’s Registration Statement on Form S-1 (the “Registration Statement”). This prospectus is filed as part of the Registration Statement pursuant to the requirements of Rule 424(b) under the Securities Act. In accordance with paragraph (e) of that Rule, the prospectus has been marked in the upper right corner to indicate that it is being filed pursuant to Rule 424(b)(4) and that the file number of the Registration Statement to which it relates is No. 333-255955.

Should any member of the Commission’s staff have any questions concerning the enclosed materials or desire any further information, please do not hesitate to contact Henry C.W. Nisser, the Executive Vice President and General Counsel of Alzamend Neuro (tel.: (646) 650-5044), or me (tel.: (212) 451-2234).